Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 461 participants.

Also called NCT02284893

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 461 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02284893
  • EudraCT 2014-001102-17
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Hungary, Mexico, Poland, Romania, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02284893. Randomized; triple masking; primary purpose treatment. Start 2014-09-09 (actual); primary completion 2016-09-20 (actual). Results posted on 2018-06-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo matching with Saxagliptin
Intervention (Drug)
Placebo matching with Dapagliflozin
Intervention (Drug)
Placebo matching with Sitagliptin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02284893
Content hash
746cb4ae37f2a42158aecfa70cb95c3c18f21a2ba38b6b8bc035e4e30319a7c0